Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-193b-3p mimic is a synthetic, double-stranded RNA oligonucleotide designed to replicate the biological activity of the endogenous mature microRNA, miR-193b-3p. In the context of neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), miR-193b-3p has been identified as a regulator of the TSC1/mTORC1 signaling axis. The mimic functions by binding to the 3' untranslated region (UTR) of the Tuberous Sclerosis 1 (TSC1) mRNA, leading to its degradation or translational repression. Since TSC1 is a critical negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1), the administration of the miR-193b-3p mimic results in the activation of mTORC1 signaling. This activation subsequently inhibits autophagy and can promote cell death in motor neurons, as demonstrated in NSC-34 cell models. While its role in ALS suggests that its downregulation may be a protective mechanism to enhance autophagy, miR-193b-3p mimics are also investigated in oncology as potential tumor suppressors due to their ability to inhibit cell proliferation and invasion in various cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-193b-3p mimic.